Scarica l'app Stockscreener
8.09
1.94%
-0.16
Dopo l'orario di chiusura:
8.15
0.06
+0.74%
Precedente Chiudi:
$8.25
Aprire:
$8.17
Volume 24 ore:
931.62K
Relative Volume:
0.56
Capitalizzazione di mercato:
$469.49M
Reddito:
$217.11M
Utile/perdita netta:
$-651.19M
Rapporto P/E:
-0.6228
EPS:
-12.99
Flusso di cassa netto:
$-387.26M
1 W Prestazione:
+19.32%
1M Prestazione:
+16.07%
6M Prestazione:
-2.18%
1 anno Prestazione:
-77.86%
Intervallo 1D:
$7.9701
$8.5819
Intervallo di 1 settimana:
$6.38
$8.69
Portata 52W:
$5.00
$45.20
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Nome
Ginkgo Bioworks Holdings Inc
Settore
Industria
Telefono
(877) 442-5362
Indirizzo
27 DRYDOCK AVENUE, BOSTON
Confronta DNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
8.09 | 469.49M | 217.11M | -651.19M | -387.26M | -12.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.89 | 124.91B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.28 | 60.05B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
587.59 | 35.88B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
230.50 | 29.83B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
228.14 | 24.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-15 | Downgrade | BTIG Research | Neutral → Sell |
| 2024-05-10 | Downgrade | William Blair | Mkt Perform → Underperform |
| 2023-11-14 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-11-09 | Downgrade | BTIG Research | Buy → Neutral |
| 2023-06-02 | Downgrade | Goldman | Neutral → Sell |
| 2023-05-11 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2022-11-29 | Iniziato | Berenberg | Buy |
| 2022-10-04 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-03-02 | Ripresa | Cowen | Outperform |
| 2022-02-23 | Iniziato | Goldman | Neutral |
| 2022-02-01 | Iniziato | BofA Securities | Neutral |
| 2022-01-28 | Iniziato | BofA Securities | Buy |
| 2022-01-07 | Iniziato | BTIG Research | Buy |
| 2021-11-29 | Iniziato | Jefferies | Buy |
| 2021-10-13 | Iniziato | Raymond James | Outperform |
| 2021-10-12 | Iniziato | William Blair | Outperform |
| 2021-09-20 | Iniziato | HSBC Securities | Buy |
Mostra tutto
Ginkgo Bioworks Holdings Inc Borsa (DNA) Ultime notizie
Ginkgo Bioworks (DNA): Building Life On Demand - Securities.io
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing - Benzinga
Ginkgo Bioworks secures $29 million ARPA-H contract By Investing.com - Investing.com South Africa
Ginkgo Bioworks secures $29 million ARPA-H contract - Investing.com Australia
Ginkgo Bioworks, Partners Awarded $29 Million Contract to Stabilize Pharmaceutical Supply Chains - MarketScreener
Wall Street Analysts Think Ginkgo Bioworks (DNA) Could Surge 41.59%: Read This Before Placing a Bet - Yahoo Finance
Ginkgo Bioworks awarded $29 million contract by Arpa-H - MarketScreener
Ginkgo Bioworks Teams Up with Partners on ARPA-H Project to Stabilize Pharmaceutical Supply ChainsUsing Amber Waves of Grain - Nasdaq
(DNA) Trading Report - news.stocktradersdaily.com
Plex Research Partners With Ginkgo Bioworks on Artificial Intelligence (AI)-Powered Drug Discovery to Identify Novel Disease Mechanisms and Pathways - Yahoo Finance
Top 5 Synthetic Biology Public Companies (April 2025) - Securities.io
Is Ginkgo Bioworks Holdings, Inc. (DNA) the Best Gene-Editing Stock to Buy? - Insider Monkey
Here's Why Ginkgo Bioworks (DNA) is Poised for a Turnaround After Losing -28.84% in 4 Weeks - Yahoo Finance
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know - MSN
Where are the Opportunities in (DNA) - news.stocktradersdaily.com
Largest borrow rate increases among liquid names - TipRanks
Ginkgo Bioworks Holdings, Inc. (DNA) Surpasses Market Returns: Some Facts Worth Knowing - MSN
(DNA) Technical Pivots with Risk Controls - Stock Traders Daily
After Plunging -52.33% in 4 Weeks, Here's Why the Trend Might Reverse for Ginkgo Bioworks (DNA) - Yahoo Finance
SBI Securities Co. Ltd. Acquires Shares of 2,905 Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - Defense World
Ginkgo Bioworks (DNA) Upgraded to Buy: Here's Why - MSN
Ginkgo Bioworks Partners with HaDEA in Up to €24 Million Consort - GuruFocus.com
Ginkgo Bioworks (DNA) Insider Trading Activity 2025 - MarketBeat
Ginkgo Bioworks CFO sells shares worth $6,102 - Investing.com India
Ginkgo Bioworks CFO sells shares worth $6,102 By Investing.com - Investing.com Australia
Ginkgo Bioworks executive sells shares for over $3k - Investing.com
Y Intercept Hong Kong Ltd Purchases New Position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) - Defense World
(DNA) Pivots Trading Plans and Risk Controls - Stock Traders Daily
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Ginkgo Bioworks Holdings, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 18, 2022DNA - ACCESS Newswire
Global Microbial Fermentation Technology Market to Increase at a Steady Growth Rate of ~5% by 2032 | DelveInsight - GlobeNewswire Inc.
Global Microbial Fermentation Technology Market to Increase at a Steady Growth Rate of ~5% by 2032 | DelveInsight - GlobeNewswire
These Analysts Think Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Sales Are Under Threat - Simply Wall St
Ginkgo Bioworks (DNA) Expected to Announce Earnings on Thursday - MarketBeat
Ginkgo Bioworks (NYSE:DNA) Shares Gap DownHere's What Happened - MarketBeat
Ginkgo Bioworks (NYSE:DNA) Posts Quarterly Earnings Results, Misses Expectations By $0.37 EPS - MarketBeat
Ginkgo Bioworks (NYSE:DNA) Posts Earnings Results - MarketBeat
DNA; SRNG Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Ginkgo Bioworks Holdings Inc. (f/k/a Soaring Eagle Acquisition Corp.) Investors of Class Action and Deadline: January 18, 2022 - ACCESS Newswire
Ginkgo Bioworks Earnings Call: Mixed Sentiments and Strategic Moves - TipRanks
Ginkgo Bioworks Shrinks Office and Lab Footprint in Boston, Cambridge - Connect CRE
Ginkgo Bioworks: Revenue Struggles Continue - Seeking Alpha
2025 Is Make Or Break For Ginkgo Bioworks (NYSE:DNA) - Seeking Alpha
Ginkgo Bioworks Holdings Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Ginkgo Bioworks: Key Takeaways from Q4 and Full-Year 2024 Earnings Report - HPBL
Cautious Outlook on Ginkgo Bioworks: Sell Rating Amid Financial and Strategic Concerns - TipRanks
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q4 2024 Earnings Call Transcript - Insider Monkey
Ginkgo Bioworks Holdings Inc (DNA) Q4 2024 Earnings Call Highlights: Strategic Restructuring ... By GuruFocus - Investing.com Canada
Ginkgo Bioworks Holdings Inc Azioni (DNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.21%
1.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):